Air pollutants have both acute and chronic impacts on human health, affecting multiple systems and organs. While PM2.5 exposure is commonly assumed to be strongly associated with all respiratory diseases, this relationship has not been systematically analyzed. This study employed a two-sample Mendelian randomization approach to investigate the effects of PM2.5 on eight common lung diseases, using data from GWAS. Additionally, multivariable Mendelian randomization was applied to assess the direct effects of various air pollutants and the mediating roles of common factors such as BMI and smoking. At a significance threshold of 5×10−8, PM2.5 showed a significant causal relationship with both asthma and COPD. When the screening threshold was relaxed to 5× 10−6, this exposure continued to demonstrate significant associations not only with asthma and COPD, but also with other respiratory diseases, including pneumonia, emphysema/chronic bronchitis, and lung cancer. In the multivariable Mendelian randomization analysis, which controlled for smoking and bacterial infections, the association with pneumonia became non-significant, while the relationships with the other four diseases persisted. This study provides a systematic exploration of the relationship between PM2.5 and eight pulmonary diseases from a new perspective, deepening our understanding of the impact of air pollution on health and laying the foundation for future efforts to mitigate these effects.
14 October 2026 in Frontiers in Cell and Developmental Biology
Background: Chronic inflammation and metabolic dysregulation are increasingly recognized as interconnected drivers of tumorigenesis and immune evasion, yet their combined prognostic and mechanistic relevance in lung adenocarcinoma (LUAD) remains poorly defined. Methods: A curated 117-gene set representing systemic inflammation-metabolism dysregulation was obtained from MSigDB. Core prognostic genes were identified through differential expression analysis and univariate Cox regression. Using TCGA-LUAD as the training cohort and six independent GEO cohorts for external validation, 101 machine learning algorithm combinations were systematically evaluated to construct a robust prognostic model. Model performance was assessed by C-index, time-dependent ROC, and PCA. Immune characteristics were analyzed using TCIA, ESTIMATE, and TIMER-based deconvolution. ATP2A2, identified as the gene most strongly correlated with risk score, underwent multi-cohort transcriptomic and immunohistochemical validation, in vitro functional characterization, and mechanistic investigation via IOBR-integrated immune profiling. Single-cell RNA sequencing and multiplex immunofluorescence provided cellular-resolution verification of microenvironmental associations. Results: The RSF + SuperPC model achieved optimal performance and effectively stratified patients into high- and low-risk groups with significantly divergent survival across all seven cohorts. High-risk tumors showed reduced immune/stromal infiltration and elevated tumor purity. ATP2A2 was consistently overexpressed in tumor tissue, correlated with poor differentiation, advanced stage, and shorter survival, and predicted immunotherapy resistance. Mechanistically, high ATP2A2 expression was associated with suppressed immune cell infiltration, attenuated chemokine signaling, impaired cancer-immunity cycle activity, and an “immune-desert” phenotype confirmed by single-cell and spatial analyses. Conclusion: This study establishes a validated inflammation-metabolism-based prognostic signature in LUAD and identifies ATP2A2 as a key driver linking tumor aggressiveness to immunosuppressive microenvironment remodeling, positioning it as a promising prognostic biomarker and potential therapeutic target for overcoming immunotherapy resistance.